William A. Weiss
William A. Weiss
Professor of Neurology, UCSF
Verified email at
Cited by
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
BE Johnson, T Mazor, C Hong, M Barnes, K Aihara, CY McLean, ...
Science 343 (6167), 189-193, 2014
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
ZA Knight, B Gonzalez, ME Feldman, ER Zunder, DD Goldenberg, ...
Cell 125 (4), 733-747, 2006
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells
J Silber, DA Lim, C Petritsch, AI Persson, AK Maunakea, M Yu, ...
BMC medicine 6, 1-17, 2008
Intertumoral heterogeneity within medulloblastoma subgroups
FMG Cavalli, M Remke, L Rampasek, J Peacock, DJH Shih, B Luu, ...
Cancer cell 31 (6), 737-754. e6, 2017
Principles and current strategies for targeting autophagy for cancer treatment
RK Amaravadi, J Lippincott-Schwartz, XM Yin, WA Weiss, N Takebe, ...
Clinical cancer research 17 (4), 654-666, 2011
Targeted expression of MYCN causes neuroblastoma in transgenic mice
WA Weiss, K Aldape, G Mohapatra, BG Feuerstein, JM Bishop
The EMBO journal, 1997
Subgroup-specific structural variation across 1,000 medulloblastoma genomes
PA Northcott, DJH Shih, J Peacock, L Garzia, A Sorana Morrissy, ...
Nature 488 (7409), 49-56, 2012
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
QW Fan, ZA Knight, DD Goldenberg, W Yu, KE Mostov, D Stokoe, ...
Cancer cell 9 (5), 341-349, 2006
Targeting MYCN in neuroblastoma by BET bromodomain inhibition
A Puissant, SM Frumm, G Alexe, CF Bassil, J Qi, YH Chanthery, ...
Cancer discovery 3 (3), 308-323, 2013
Neuroblastoma and MYCN
M Huang, WA Weiss
Cold Spring Harbor perspectives in medicine 3 (10), a014415, 2013
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
SC Mack, H Witt, RM Piro, L Gu, S Zuyderduyn, AM Stütz, X Wang, ...
Nature 506 (7489), 445-450, 2014
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma
H Witt, SC Mack, M Ryzhova, S Bender, M Sill, R Isserlin, A Benner, ...
Cancer cell 20 (2), 143-157, 2011
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Z An, O Aksoy, T Zheng, QW Fan, WA Weiss
Oncogene 37 (12), 1561-1575, 2018
Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma
N Zhukova, V Ramaswamy, M Remke, E Pfaff, DJH Shih, DC Martin, ...
Journal of Clinical Oncology 31 (23), 2927-2935, 2013
Clonal selection drives genetic divergence of metastatic medulloblastoma
X Wu, PA Northcott, A Dubuc, AJ Dupuy, DJH Shih, H Witt, S Croul, ...
Nature 482 (7386), 529-533, 2012
BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
P Bandopadhayay, G Bergthold, B Nguyen, S Schubert, S Gholamin, ...
Clinical Cancer Research 20 (4), 912-925, 2014
Pediatric high-grade glioma: biologically and clinically in need of new thinking
C Jones, MA Karajannis, DTW Jones, MW Kieran, M Monje, SJ Baker, ...
Neuro-oncology 19 (2), 153-161, 2017
Cytogenetic prognostication within medulloblastoma subgroups
DJH Shih, PA Northcott, M Remke, A Korshunov, V Ramaswamy, M Kool, ...
Journal of clinical oncology 32 (9), 886-896, 2014
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
EM Thompson, T Hielscher, E Bouffet, M Remke, B Luu, S Gururangan, ...
The lancet oncology 17 (4), 484-495, 2016
The system can't perform the operation now. Try again later.
Articles 1–20